Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group.
Aged
Aged, 80 and over
Brachytherapy
/ methods
Case-Control Studies
Endometrial Neoplasms
/ pathology
Female
France
/ epidemiology
Humans
Middle Aged
Neoplasm Recurrence, Local
/ epidemiology
Neoplasm Staging
Practice Guidelines as Topic
Radiotherapy, Adjuvant
/ methods
Retrospective Studies
Risk Factors
Brachytherapy
Endometrial Cancer
Local Neoplasm Recurrence
Journal
Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
10
07
2018
revised:
26
11
2018
accepted:
09
01
2019
pubmed:
11
5
2019
medline:
10
3
2020
entrez:
11
5
2019
Statut:
ppublish
Résumé
According to recent European Society of Medical Oncology, European Society of Gynaecological Oncology and European Society of Radiotherapy and Oncology guidelines, adjuvant vaginal brachytherapy (VB) is optional in patients with intermediate risk (IR) and high-intermediate risk (HIR) endometrial cancer (EC). The aim of this French retrospective, multicenter study was to assess the impact of VB in these groups on local recurrence rate, local recurrence-free survival (RFS) and overall survival (OS). Data of 191 patients with IR and HIR EC who underwent primary surgery with or without VB and no other adjuvant treatment between 2000 and 2016 were extracted from the FRANCOGYN database. Rate of local recurrence, OS and local RFS in these two groups were compared using the Kaplan-Meier method. The number of patients with IR and HIR EC were 118 and 73 respectively. VB was used in 92 patients in IR group and 43 in HIR group. Median follow-up was 22 months. In the HIR group, the local recurrence rate was significantly higher in the no adjuvant therapy group in comparison with the VB group (16.7% and 0% respectively, p=0.02). There was also a significant improvement in local RFS (p=0.01) in VB group. In IR EC, there is no significant difference on local recurrence rate (4.2% and 3.2%, respectively, p=1.00) or local RFS (p=0.54) between the two groups. VB is an efficient adjuvant treatment for patients with HIR EC. VB is not associated with an improvement of RFS or OS in IR EC patient.
Identifiants
pubmed: 31074238
pii: 30.e53
doi: 10.3802/jgo.2019.30.e53
pmc: PMC6543117
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e53Informations de copyright
Copyright © 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Lancet. 2000 Apr 22;355(9213):1404-11
pubmed: 10791524
Gynecol Oncol. 2002 Dec;87(3):243-6
pubmed: 12468320
Gynecol Oncol. 2004 Mar;92(3):744-51
pubmed: 14984936
Gynecol Oncol. 2005 Mar;96(3):799-804
pubmed: 15721428
Gynecol Oncol. 2006 Oct;103(1):87-93
pubmed: 16545441
Eur J Surg Oncol. 2007 Jun;33(5):644-7
pubmed: 17317084
Lancet. 2009 Jan 10;373(9658):137-46
pubmed: 19070891
Anticancer Res. 2009 May;29(5):1715-20
pubmed: 19443392
Ann Oncol. 2009 May;20 Suppl 4:29-31
pubmed: 19454455
Int J Gynecol Cancer. 2009 Jul;19(5):873-8
pubmed: 19574776
Lancet. 2010 Mar 6;375(9717):816-23
pubmed: 20206777
Gynecol Oncol. 2011 Apr;121(1):169-73
pubmed: 21159367
Gynecol Oncol. 2012 Jan;124(1):31-5
pubmed: 22030404
Bull Cancer. 2012 Jan;99(1):7-12
pubmed: 22231875
Int J Gynecol Cancer. 2012 May;22(4):703-8
pubmed: 22398710
Int J Gynecol Cancer. 2012 Sep;22(7):1281-8
pubmed: 22864336
J Natl Cancer Inst. 2012 Nov 7;104(21):1625-34
pubmed: 22962693
Gynecol Oncol. 2013 Oct;131(1):231-40
pubmed: 23872191
Pract Radiat Oncol. 2014 May-Jun;4(3):137-144
pubmed: 24766678
Ann Surg Oncol. 2015;22(6):1980-6
pubmed: 25391264
Gynecol Oncol. 2015 Mar;136(3):521-8
pubmed: 25562668
Eur J Obstet Gynecol Reprod Biol. 2015 Mar;186:63-7
pubmed: 25638600
Eur J Cancer. 2015 Sep;51(13):1742-50
pubmed: 26049688
Int J Gynecol Cancer. 2015 Oct;25(8):1526-33
pubmed: 26207785
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):797-809
pubmed: 26530748
Int J Gynecol Cancer. 2016 Jan;26(1):2-30
pubmed: 26645990
Gynecol Oncol. 2016 Aug;142(2):278-82
pubmed: 27261326
Cancer Radiother. 2016 Sep;20 Suppl:S189-95
pubmed: 27523423
Gynecol Oncol. 2017 Jan;144(1):107-112
pubmed: 27789083
Br J Cancer. 2016 Nov 22;115(11):1296-1303
pubmed: 27824810
Gynecol Obstet Fertil Senol. 2017 Dec;45(12):715-725
pubmed: 29132772